cyrilzakka/clinical-trials huggingface dataset:
HD+ I-scan Bronchoscopy Vascular Abnormalities Detection Multicenter Study

Videobronchoscopy is an essential diagnostic procedure for evaluation of the central airways and pivotal for the diagnosis and staging of lung cancer. Further technological improvements have resulted in high definition (HD+) images and advanced image enhancement technique (i-scan). An earlier study (NCT01676012) has indicated that HD+ bronchoscopy in combination with i-scan technology is superior to HD+WL (white light) for detecting endobronchial vascular changes. In this study we aim to correlate these vascular changes to histology and hypothesize that these vascular changes are related to (pre-) malignant changes and that the addition of i-scan is superior to HD+ WL.

Patients will undergo a bronchoscopy with Pentax EB1990i HD-bronchoscope in combination with Pentax EPKi series videoprocessor investigating the entire bronchial tree. Bronchoscopy will be performed by an experienced chest physician under local anaesthesia use and type of sedation following local protocol. Bronchoscopy will be performed in a standardized order using three different imaging modes. The order of the different modes will be randomized to avoid induced scope and / or cough lesion bias. High definition digital videos will be made from all procedures without in screen patient identification, but using a study code. The three imaging modes used in this study are: HD+, HD+ surface enhancement (SE, i-scan1) and HD+ surface enhancement and tone enhancement (TE-c, i-scan2).

When sites with abnormal or suspicious vascular patterns are detected the investigator grade these findings using a visual classification scale \[adapted from Herth JTO 2009 \& Zaric Med Oncol 2013\] and change to a regular bronchoscope and take biopsies from each site and a biopsy from a normal secondary carina on the contralateral site as control. Finally any other indicated procedures will be performed at the discretion of the local investigator.

Eligibility Criteria:
Inclusion Criteria:

* Patients with indication for diagnostic bronchoscopy for suspected or proven lung cancer.
* ASA physical status 1-3.
* Age 18 years or older.
* Signed and dated patient informed consent.

Exclusion Criteria:

* Bleeding disorders.
* Indication for use of anticoagulant therapy (acenocoumarol, warfarin, therapeutic dose of low molecular weight heparines or clopidrogel).
* Known allergy for lidocaine.
* Known pulmonary hypertension.
* Recent and/or uncontrolled cardiac disease.
* Compromised upper airway (eg concomitant head and neck cancer or central airway stenosis for any reason).
* ASA classification greater than or equal to 4.
* Pregnancy.
* Inability to consent.
A Study of LY3471851 in Participants With Eczema

The main purpose of this study is to learn more about the safety and side effects of LY3471851 when given by injection just under the skin to participants with eczema. The study will last up to 48 weeks and may include up to 23 visits to the study center.


Eligibility Criteria:
Inclusion Criteria:

* Have a confirmed diagnosis of atopic dermatitis (AD) for least 12 months
* Have active AD according to study specific criteria
* Be willing and able to undergo skin biopsies

Exclusion Criteria:

* Have received certain topical medications for AD within 14 days prior to baseline
* Have received certain systemic medications for AD within 4 weeks prior to baseline
* Have received LY3471851 previously
Speed of Glucose Absorption During Exercise

The purpose of this study is to look at how fast commercially available supplements containing carbohydrates can get into the bloodstream during repeated sprint cycles. This will build from a pervious study where the investigators tested these supplements on healthy participants during a resting oral glucose tolerance trial. The investigators will be testing three supplements, namely Voom Pocket Rocket, SIS Go Isotonic Energy Gel, and Maurten Gel 160. Each participant will complete all three conditions, consuming one of each supplement at random per condition. The study requires participation from male and female runners, cyclists and triathletes who are aged between 18-40.

Each visit will take approximately 1 hour, and three experimental visits per participant. The study will involve frequent blood sampling and the continuous monitoring of gas exchange (oxygen/carbon dioxide). Blood sampling via cannulation will be used to analyse the lactate, glucose, and electrolyte content of the blood. Gas exchange will measure the oxygen breathed in and carbon dioxide breathed out throughout the exercise.

The investigators plan to carry out the study on 10 participants who will be a mix of male and female runners, cyclists and triathletes.


Eligibility Criteria:
Inclusion Criteria:

* Aged between 18-40 years
* Male or female
* Tier 2 athletes - local level representation, training \~ 3 times per week, training with a purpose to compete, identify with a specific sport, limited skill development (McKay et al., 2021)

Exclusion Criteria:

* Allergies to any listed ingredients on any supplements.
* Diabetes (type 1 or 2)
* Any medical conditions
* Smokers
* Any injury that would prevent them from exercising
* Anyone using drugs or medication (not including contraception)
* Anyone consuming alcohol within 24 hours of the study
* Exercise must be restricted within 24 hours of the study
* Caffeine must not be consumed within 24 hours of testing as it can significantly enhance carbohydrate oxidation rates (Yeo et al., 2005)
* Diets including high-carbohydrate-low-fat (HCLF), low-carbohydrate-high-fat (LCHF), ketogenic, and/or glycogen manipulation diets (Rauch et al., 2022)
Inguinal Hernia Repair and Male Fertility

General objective: To evaluate the fertility of adult men submitted to bilateral herniorrhaphy with mesh placement by the Lichtenstein and laparoscopic approaches

Specific objectives: To correlate pre and postoperative data (90 and 180 days) of adult men, according to biochemistry parameters (hemogram and CRP), autoimmune (anti-sperm antibodies), hormonal (FSH, LH and testosterone), perfusion and volume testicular (USG of testicles with Doppler), spermogram, sexual changes, pain and quality of life (standard questionnaires).

Eligibility Criteria:
Inclusion Criteria:

* Male
* Age between 19 and 60 years old
* Bilateral inguinal hernia
* Primary and reducible inguinal hernia

Exclusion Criteria:

* Age less than 19 or more than 60 years old
* ASA \>III
* Genito-urinary infection
* Immunodeficiency
* History of testicular trauma2
* History of surgery or pelvic radiotherapy
* History of testicular disease
* Fertility problems or sexual
* Illness that can be infertile
* Recurrent hernia
* Unilateral hernia
* Femoral or inguine-scrotal hernia
* Imprisoned hernia
* Use of Gonadotrophins
* Use of anabolic steroids
Pain Relief During Unsedated Office Hysteroscopy by Applying TENS

Aim: To compare the pain-relieving effect of a specific application of TENS vs. placebo TENS and a control group during unsedated diagnostic office hysteroscopy.

Design: double-blind randomized placebo-controlled trial. Setting: Outpatient setting. Population: Women who attended annual gynecological check up, and were indicated for diagnostic office hysteroscopy.

Nowadays, diagnostic hysteroscopy is an easy and economically acceptable technique, that is being used by the gynecologist to evaluate different pathologies that used to be studied by other blind techniques. Although most women tolerate it well, the most common cause for failure during office hysteroscopy is pain. In order to overcome this adversity several studies have been carried out using different types of pain relievers as local anesthesia, misoprostol, music, and NSAID to prevent the occurrence of a vagal reaction, but the results have been contradictory. Other analgesic alternatives that prioritize these three points should be considered. Transcutaneous electrical nerve stimulation (TENS) has become a very common electrotherapy as a pain-reliever because of its attributes, namely a noninvasive and non-pharmacological method based on the delivery of pulsed electrical currents through the skin, using surface electrodes, effective in many variety of conditions, such as neuropathic pain, musculoskeletal pain, headache, gynecological and obstetric pain, to treat both chronic and acute pain, even from visceral organs.

Aim: to compare the pain-relieving effect of a specific application of TENS vs. placebo TENS and a control group during unsedated diagnostic office hysteroscopy.

Design: double-blind randomized placebo-controlled trial. Setting: Outpatient setting; Hospital Provincial de Castellon (Spain) and Hospital General de Castellon (Spain).

Population: Women who attended annual gynecological check up, and were indicated for diagnostic office hysteroscopy

Eligibility Criteria:
Inclusion Criteria: women who attended annual gynecological check up, and were indicated for diagnostic office hysteroscopy because of different pathologies such as:

* postmenopausal endometrial thickening \>4mm;
* postmenopausal abnormal uterine bleeding;
* suspicious endometrial polyp or leiomyoma;
* infertility study;
* suspicious endometrial carcinoma;
* hypermenorrhea

Exclusion Criteria:

* age less than 18;
* previous cervical surgery;
* neurological deficit;
* chronic or preprocedural use of opioids or psychoactive drugs;
* previous experience in TENS;
* cutaneous damage on the application sites;
* pacemakers or automatic implanted cardiac defibrillators;
* refusal to sign the informed consent form;
* inability to understand informed consent form.
Innovative Patient-partner-guided Virtual Group Speech Pathology Intervention Model in Head and Neck Cancer

This project aims to study an innovative intervention, the eG2 Intervention, developed by speech-language pathologists at the Centre hospitalier de l'Université de Montréal to improve therapeutic adherence and prevent dysphagia in patients treated with chemoradiotherapy for head and neck cancer.

The innovation consists in offering a speech therapy intervention that is 1) virtual, 2) group-based (whereas it is usually individual) and 3) involves a patient partner. This intervention has the potential to improve quality of care, accessibility to services and optimize health care resources.


Eligibility Criteria:
Inclusion Criteria:

* Adults ≥ 18 years of age with a diagnosis of head or neck cancer
* Chemoradiotherapy treatments planned for curative purposes
* Planned external radiation therapy dose of at least ≥60 Grays
* Sufficient proficiency in French to complete self-reported questionnaires

Exclusion Criteria:

* Remote metastases
* Previous or planned total laryngectomy
* Previous moderate/severe dysphagia known and/or evaluated by speech therapy
* Diagnosis of a second synchronous cancer at the time of study enrollment
* History of prior radiation therapy to the head and neck area
* Have a cognitive impairment (diagnosed or suspected) that may significantly interfere with participation in the intervention and various measurement procedures.
Management of Severe Congenital Blepharoptosis

Frontalis sling surgery was carried out using Ptose-up under general anaesthesia for patients with severe congenital ptosis.

Frontalis sling surgery was carried out using Ptose-up for patients with severe congenital ptosis in 23 eyes of 15 patients and they followed up for at least 6 months to detect the success rate and if there is any postoperative complications.

Eligibility Criteria:
Inclusion Criteria:

* Severe congenital blepharoptosis
* Poor levator muscle function
* No previous ptosis surgery

Exclusion Criteria:

* Patients with Jaw winking phenomenon
* Blepharophimosis syndrome
* Congenital myasthenia
RTLS Technology Study

This study will examine the productivity of the hospital workforce utilizing a unique dataset that is stored at the Royal Wolverhampton Trust (RWT). The data is recorded by a Real Time Location System (RTLS) that tracks the second-by-second physical location of patients, staff, and medical equipment. Using this data, the plan is to measure the amount of time that clinical staff spend with patients and with other clinical staff, and then explore how these measures of contact time influence patient health outcomes. The data will also be used to measure the location and movement of patients during their hospital stay, and test the impact of moving patients between wards on their health outcomes. In light of the recent COVID-19 outbreak, impact of COVID19 on patient contact time, patient outcomes and professional working practices will also be examined.


Eligibility Criteria:
Inclusion Criteria:

* Patients admitted to inpatient departments at RWT and are present at RWT during the period of 1 April 2016 to 31 March 2019 inclusive.

Exclusion Criteria:

* Patients admitted to outpatient wards at RWT;
* Patients that were not admitted at or discharged from RWT between 1 April 2016 to 31 March 2019 inclusive.
Immunogenicity and Safety Study of Rotarix TM in Taiwanese Infants Who Received Hepatitis B Immunoglobulin After Birth.

The purpose of this study is to assess immunogenicity and safety of Rotarix TM when administered in healthy Taiwanese infants (aged 6 to 12 weeks at the time of first vaccination) who received Hepatitis B immunoglobulin after birth.


Eligibility Criteria:
Inclusion Criteria:

* Subjects who the investigator believes that parent(s)/Legally Acceptable Representative(s) can and will comply with the requirements of the protocol.
* A male or female between, and including, 6 and 12 weeks of age at the time of the first vaccination.
* Written informed consent obtained from the parent(s)/Legally Acceptable Representative(s) of the subject.
* Healthy subjects as established by medical history and clinical examination before entering into the study.
* Infants who have received a previous dose of hepatitis B immunoglobulin after birth.

Exclusion Criteria:

* Child in care.
* Use of any investigational or non-registered product other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period.
* Chronic administration of immunosuppressants or other immune-modifying drugs with the exception of Hepatitis B immunoglobulin since birth. Child is unlikely to remain in the study area for the duration of the study.
* Planned administration/administration of a vaccine not foreseen by the study protocol within 30 days of the first dose of vaccine.
* Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.
* Previous vaccination against rotavirus.
* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
* Family history of congenital or hereditary immunodeficiency.
* History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine.
* Major congenital defects or serious chronic illness.
* Acute disease and/or fever at the time of enrolment.
* Administration of immunoglobulins (with the exception of HBIG) and/or any blood products since birth or planned administration during the study period.
* Gastroenteritis within 7 days preceding the study vaccine administration.
* Previous confirmed occurrence of Rotavirus gastroenteritis.
Sympathetic Nervous System Modulation in Hypertension

This is a study of patients with high blood pressure who are already treated with an angiotensin converting enzyme inhibitor or receptor blocker and have achieved good or fair blood pressure control. The hypothesis is that addition of the beta-adrenergic receptor blocker, sustained-release metoprolol, will provide additional blockade of the sympathetic nervous system, thereby further improving left ventricular filling and blood pressure control.

Patients were to receive sympathetic cardiac innervation testing with I-123 MIBG at baseline and again after receiving a titrate dose of beta-blocker. Data were to be assesses by repeated measures testing.

Eligibility Criteria:
Inclusion Criteria:

* Essential hypertension with blood pressure less than 140/90 on either an ACE inhibitor or angiotensin receptor blocker

Exclusion Criteria:

* Known valvular heart disease of more than mild severity
* Known coronary artery disease defined by an angiographic coronary artery stenosis greater than or equal to 50% luminal diameter narrowing, acute or previous myocardial infarction, or previous coronary revascularization
* Known non-ischemic cardiomyopathy with left ventricular ejection fraction less than 50%
* Atrial fibrillation
* Current treatment with a β-adrenergic blocking drug or a calcium channel blocker
* Current treatment with a psychoactive or other drug known to alter 123I-MIBG uptake
* Participation in another research study within the prior 30 days
* A life-limiting disease process that is likely to preclude completion of study participation
* Pregnancy or breast feeding
* Inability or unwillingness to provide informed consent
* Baseline resting heart rate less than 65 beats per minute
* Diabetes
* Iodine allergy
* Unwilling to sign informed consent.
Compared Efficacy and Tolerance of Two Vasopressors Used to Treat Preoperative Hypotension During Carotid Surgery

The effects on brain perfusion of the two currently vasopressors used to treat accidental hypotension occurring during carotid surgery (i.e. ephedrine and phenylephrine) is not known, but a disadvantage to use phenylephrine is suspected, due to its mechanism of action and according to published reports

This is a randomised trial comparing ephedrine and phenylephrine as used for accidental hypotension occurring during carotid surgery, on cerebral perfusion, assessed by near-infrared spectroscopy (NIRS).

Eligibility Criteria:
Inclusion Criteria:

* Age over 18 ASA score I-III Planned carotid endarteriectomy under general anaesthesia Hypotension defined as SAP \< 90 mm Hg during general anaesthesia Informed consent to the trial Protected by the French health welfare

Exclusion Criteria:

* Emergency surgery Cardiac arrythmia Pregnancy or breastfeeding Allergy to the tested treatment Allergy to hydroxyethylstarch Allergy to the glue of the NIRS's electrodes Current medication: MAOI, intranasal vasopressors
Study to Evaluate Real-world Effectiveness With Palbociclib Plus Endocrine Therapy as First-line/Second-line Treatment for HR+/HER2- Advanced Breast Cancer in Japan

This is a retrospective, multicenter, observational study in Japan by medical record review of advanced breast cancer (ABC) patients who have received palbociclib plus endocrine therapy (ET) as first line or second line setting. For the purposes of this study, analyses will be descriptive in nature. No formal hypothesis testing is planned.


Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of HR+/HER2- ABC
* Age of 20 years or older at diagnosis of ABC
* Patients that received palbociclib plus ET in the first line or second line
* Patients who meet the criteria regarding the medical record below:
* Patients with any medical records (regardless of palbociclib use) for more than 6 months from palbociclib initiation OR
* Patients with any medical records for less than 6 months from palbociclib initiation AND who had specific events (death, disease progression, or treatment discontinuation of palbociclib due to adverse events) in the available records

Exclusion Criteria:

* Patients who received chemotherapy as first line treatment.
* Patients who have previously participated or are participating in any interventional clinical trials that include investigational or marketed products.

(Interventional clinical trials for early breast cancer and later line after palbociclib will be acceptable, Besides, patients participating in other investigator-initiated research or noninterventional studies can be included as long as their standard of care is not altered by the study.)
Integrated Treatment of Marijuana Abuse for HIV+ Youth

This is an exploratory study that will adapt and test a combined cognitive behavioral treatment and contingency management intervention for alcohol and/or marijuana abuse for use in HIV-infected adolescents.


Eligibility Criteria:
Inclusion Criteria:

* Adolescents between the ages of 16-24 years (inclusive) at the time of informed consent/assent as determined by medical record review or verbal verification from referring professional
* HIV-infected and aware of their status as documented by medical record review or verbal verification from referring professional
* Receives services at one of the three participating ATN clinic site or their community partners
* A score of 2 or greater on the CRAFFT indicating possible alcohol or marijuana use problem or abuse
* Alcohol and/or Marijuana Use or Abuse Disorder as indicated by the SSPQ-X
* Appropriate for an outpatient or intensive outpatient level of care in accordance with the American Academy of Child and Adolescent Psychiatry practice parameters as decided by site mental health provider in consultation with Drs. Brown and Esposito-Smythers
* English-speaking
* Ability and willingness to provide informed consent/assent for study participation
* Satisfactorily understands the nature of the study and the informed consent process as documented by the Consent Form Comprehension Assessment Questionnaire

Exclusion Criteria:

* Presence of serious psychiatric symptoms (e.g., active hallucinations, thought disorder)
* Visibly distraught (e.g., suicidal, homicidal, exhibiting violent behavior)
* Intoxicated or under the influence of alcohol or other substances at the time of study entry
Survey on the Characteristics of Traditional Medicine Syndromes in Urticaria Patients At Le Van Thinh Hospital

This study aims to investigate the characteristics of Traditional Medicine (TM) syndromes in urticaria patients at Le Van Thinh Hospital. Urticaria is a common dermatological condition that significantly impacts patients' quality of life. However, there is limited research on TM syndrome classification in this patient group. The study will collect data on symptoms, TM syndromes, and disease severity to determine common syndromes and their associations with clinical manifestations.

The study will be conducted as a cross-sectional, observational study with an estimated 200 participants. Eligible patients are those aged 18 years or older, diagnosed with acute or chronic urticaria, and willing to participate. The primary outcomes include the prevalence of TM syndromes, itching severity measured by the Visual Analogue Scale (VAS), and the correlation between TM syndromes and itching severity.

The study is approved by the Institutional Review Board (IRB) of the University of Medicine and Pharmacy at Ho Chi Minh City and will be conducted from December 2024 to April 2025 at Le Van Thinh Hospital, Vietnam.


Eligibility Criteria:
Inclusion Criteria:

* Patients aged 15 years or older.
* Diagnosed with acute or chronic urticaria based on modern medical criteria.
* Willing to participate and provide informed consent.

Exclusion Criteria:

* Patients with other dermatological conditions that may interfere with the diagnosis of urticaria.
* Patients currently using medications that may alter symptom presentation (e.g., antihistamines, corticosteroids, immunosuppressants).
* Patients who refuse to participate in the study